Form 4: Director Gregory Matz Receives Stock Options in DARE

Director Gregory W. Matz was granted 10,000 stock options in Dare Bioscience, Inc. as part of his compensation.

Summary

• Director Gregory W. Matz acquired 10,000 stock options in Dare Bioscience, Inc. (DARE).
• The options have an exercise price of $2.03 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Dilutive effect of new option grants on existing shareholders.

Risks

• The value of the options is dependent on the future performance of DARE common stock.
• Vesting is subject to the director's continued service.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders following the grant, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common practice among small-cap biotech firms to preserve cash while incentivizing board oversight.
• The vesting schedule is consistent with standard industry practices for director equity compensation.

Stakeholder Impact

• Minor dilution for existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on the earlier of June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Dare Bioscience, DARE, Form 4, Insider Trading, Stock Options, Director Compensation